COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company has hired a Swiss contract research organization (CRO) to supervise the planned Phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte® in traumatic brain injury (TBI). The CRO for the proposed trial will be PFC Pharma Focus AG. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
